x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Bio Report

Levine Media Group

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

science life sciences

All Episodes

25:47

Developing an Alternative to Opioids for...

The Bio Report ·

2025/12/24

The approach to post-surgical pain relief has relied on short-duration treatments and notably opioids. That’s led to the associated risks of dependence and abuse, prolonged hospitalizations, and slower recoveries. Allay Therapeutics is developing an alternative to opioids to treat post-surgical pain with an initial focus on knee replacement surgeries. Allay’s guitar pick-sized polymer is implanted during surgical procedures and it releases the analgesic bupivacaine as it dissolves over 30 days. We

en

22:19

Leveraging the Power of Vocal Biomarkers

The Bio Report ·

2025/12/17

Physicians can learn a lot from talking to patients, and not just from the words they say, but from millions of data points from acoustic features of their speech, such as pitch, vocal cord vibration patterns, and micro-instabilities in the voice. Canary Speech has developed an AI-based diagnostic listening tool that can detect neurological and psychiatric conditions from physiological signals in the voice. We spoke to Kang Hsu, chief medical officer of Canary Speech, about how its diagnostic tool

en

37:09

Determining the Cause and Severity of Sepsis with a...

The Bio Report ·

2025/12/10

Sepsis remains one of medicine’s most intractable and costly problems, arising when an infection triggers a runaway immune response that damages organs long after a pathogen is controlled. It accounts for an estimated $53 billion in Medicare spending alone, yet more than a hundred drug trials have failed to yield a single approved drug that directly treats the underlying immune dysfunction. Inflammatix, which grew out of work at Stanford University, has developed a point-of-care blood test to

en

32:21

Separating Signal from Noise in Regenerative Therapies

The Bio Report ·

2025/12/03

Rion is developing platelet-derived exosome therapeutics as off-the-shelf, room-temperature-stable alternatives to traditional cell therapies. The company’s lead program is advancing toward phase 3 trials in diabetic foot ulcers, and it is building a broader pipeline across musculoskeletal, cardiovascular, pulmonary, dermatologic, and women’s health indications. The company is built on stem cell research conducted at the Mayo Clinic that showed that regenerative benefits from treatments stemmed from

en

45:49

Rewriting Drug Discovery with an AI-Multi-Omics Approach

The Bio Report ·

2025/11/26

The genomics revolution promised to unravel diseases and lead to treatments that addressed their root causes. In reality, says Mo Jain, your zip code remains a better predictor for how healthy you will be over the course of your life than your genetic code does. That’s because, except for monogenic diseases, etiology tends to be far more complex than the identification of a single gene. Sapient Bio company is using its AI-driven, multi-omics platform to advance the discovery and development of

en

36:24

Overcoming Chemoresistance and Activating the Immune...

The Bio Report ·

2025/11/19

The enzyme GSK3β, in healthy cells, is involved in glucose metabolism. In cancer cells, though, it serves as a master regulator of tumor growth, progression, and cell survival. While GSK3β has long been an attractive target in cancer therapy, it has been difficult to inhibit due to the poor pharmaceutical characteristics and adverse effects of therapeutic candidates. Actuate Therapeutics’ experimental therapy elraglusib has shown early promise. Results suggest it not only suppresses tumor growth but

en

21:26

A Hub-and-Spoke Ophthalmology Company with an Eye for...

The Bio Report ·

2025/11/12

Hub-and-spoke business models—the use of a central core of business functions with pipeline assets spun out into subsidiary companies—have gained traction for the benefits they can provide in terms of capital efficiency, diversification of risks, and improved access to capital. Eyexora is applying that business model to accelerate the development of therapies for ophthalmic indications. We spoke to Theresa Heah, CEO of Eyexora, about why the hub-and-spoke model is well-suited for the development of

en

55:46

An AI Collaborative that Welcomes All into the Fold

The Bio Report ·

2025/11/05

OpenFold, an open-source, collaborative initiative founded in 2022 to address the challenges of protein structure prediction and design using artificial intelligence, emerged as a response to the restricted commercial access to DeepMind’s AlphaFold platform. Leveraging public datasets and using a pre-competitive consortium model, OpenFold seeks to democratize cutting-edge protein engineering tools for both industry and academia. We spoke to Brian Weitzner, director of computational and structural

en

42:46

Hitting the Reset Button on Cellular Aging

The Bio Report ·

2025/10/29

Transcription factors control the genetic programs that maintain cellular balance, but while they have been seen as compelling targets for aging-related disease, they have long been considered “undruggable.” Junevity’s RESET platform leverages large-scale human omics data and AI models to pinpoint key transcriptional drivers of disease and to design siRNA therapies that restore healthy gene expression. We spoke to John Hoekman, co-founder and CEO of Junevity, about the role of transcription factors

en

29:58

Changing the Ovarian Cancer Treatment Landscape with...

The Bio Report ·

2025/10/22

Ovarian cancer remains one of the deadliest cancers affecting women, and it is expected to claim nearly 13,000 lives in the United States in 2025. Despite progress in survival rates, nearly 80 percent of patients are still diagnosed at advanced stages, when the disease has already spread and is difficult to treat. Imunon’s experimental DNA-mediated immunotherapy is designed to deliver interleukin-12 directly into the tumor. A phase 2 study demonstrated that the experimental therapy, when combined

en

32:39

Why the United States Must Fall in Love with...

The Bio Report ·

2025/10/15

China’s emergence as a biotech superpower may have appeared to happen suddenly, but it reflected a long-term vision and policies over many years that enabled its success. As biotechnology transforms not only medicine but also industries such as food, fuel, and materials, the competition between China and the United States to shape the future bioeconomy is intensifying. We spoke to Drew Endy, associate professor of bioengineering and senior fellow of the Hoover Institution at Stanford University,

en

39:48

Transforming Drug Discovery and Disease Research—One...

The Bio Report ·

2025/10/08

The ARC Virtual Cell Atlas uses high-throughput single-cell genomics, artificial intelligence, and open science to understand the complexities of cellular behavior. Developed through a partnership between the ARC Institute, 10x Genomics, and Ultima Genomics, the public domain resource integrates data from hundreds of millions of cells. By curating and harmonizing vast amounts of single-cell measurements, the Atlas paves the way for virtual cell simulations that can predict how cells respond to

en

24:30

Scratching the Surface with a Novel Approach to...

The Bio Report ·

2025/10/01

Bronchopulmonary dysplasia is a condition that affects preterm infants, especially those born with underdeveloped lungs who require prolonged oxygen therapy or mechanical ventilation to help them breathe after birth. It is characterized by damage and abnormal development of the lung tissue and airways, often resulting from life-saving interventions necessary for babies born very prematurely. Airway Therapeutics is developing a new class of biologics for respiratory and inflammatory diseases,

en

29:37

A Dual Action Approach to Treating MASH

The Bio Report ·

2025/09/24

MASH, a chronic and progressive form of fatty liver disease that until recently was known as NASH, affects millions of people in the United States, and its incidence continues to rise. In fact, MASH is now among the leading causes of liver transplantation in the United States. 89bio is developing an experimental therapy to target multiple disease mechanisms of the condition. We spoke to Rohan Palekar, CEO of 89bio, about what’s driving the prevalence of MASH, the limits of existing medicines, and

en

30:20

Extending the Life of Transplanted Kidneys

The Bio Report ·

2025/09/17

The average kidney transplant recipient experiences kidney failure within 10 to 12 years after a transplant, putting them on a cycle that ends with kidney failure and a need for a new transplant. This cycle adds to strains on transplant recipients, payers, providers, and the healthcare system and taxes the limited supply of organs for transplantation. Eledon Pharmaceuticals is seeking to extend the functional life of transplanted organs while reducing the side effects of current immunosuppressive

en

35:25

Overcoming Antimicrobial Resistance

The Bio Report ·

2025/09/10

Antimicrobial resistance is projected to kill up to 10 million people a year by 2050. One particular area of concern is drug-resistant gonorrhea, where existing therapies are being exhausted. Taxis Pharmaceuticals is developing therapies to combat evolving superbugs by targeting their cellular infrastructure and disrupting the mechanisms that fuel antimicrobial resistance. We spoke to Greg Mario, president and CEO of Taxis, about the public health threat posed by drug-resistant gonorrhea, the

en

36:30

Using Targeted Radiotherapies to Treat Challenging...

The Bio Report ·

2025/09/03

Brain tumors are difficult to treat in part because of the blood-brain barrier, the need to protect healthy and sensitive tissue surrounding tumors, and the limits of existing therapies. While there have been great advances in other types of cancer, there’s been relatively little progress in treating these CNS tumors. Plus Therapeutic is developing targeted radiotherapies that provide high doses of radiation directly into the tumor with a catheter. The approach enables the delivery of higher doses

en

02:33

Hitting Previously Undruggable Targets with Oral...

The Bio Report ·

2025/08/27

Macrocycles are complex compounds that can interact with targets that are often unreachable with traditional small molecules. Orbis Medicines is addressing the challenge with its nCycles, synthetic macrocycle drugs that are orally available but hit targets that would otherwise require biologic therapies. We spoke to Morten Graugaard, co-founder and CEO of Orbis Medicines, about its class of synthetic macrocycles called nCycles, its platform technology to generate and screen these therapies, and how

en

30:49

Building Better Models of Human Diseases to Speed...

The Bio Report ·

2025/08/20

Animal testing for experimental therapies is slow, expensive, and an imperfect predictor for how a drug will act in humans. The Foundation for the National Institutes of Health in July announced a program to advance innovative laboratory technologies that model human biology, enabling faster, less expensive testing. We spoke to Stacey Adam, vice president of scientific partnerships for the FNIH and leader of the public-private partnership, about the new program, the technologies being explored, and

en

38:13

Preventing Opioids from Countering the Benefits of...

The Bio Report ·

2025/08/13

Many cancer patients are prescribed opioids to manage pain associated with their disease, but studies have shown that the use of these pain killers naturally mutes the immune response and can reduce the efficacy of immunotherapies. Glycyx Therapeutics is developing a drug it believes can allow opioids to relieve pain while preventing them from working against immunotherapies. We spoke to Lorin Johnson, chief scientific officer of Glycyx Therapeutics, about the effect of opioids on the immune system,

en

299 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter